Go figure. GlaxoSmithKline
Pharmaceutical companies like Pfizer
Terms of the agreement weren't disclosed, but it looks like a good idea for both companies. Dr. Reddy's gets to expand its sales with minimal effort -- it'll co-market the drugs in some markets and take royalties in the rest. For Glaxo, the expanded portfolio of drugs will help the drugmaker use its international sales, marketing, and distribution system more effectively.
Big pharma -- Glaxo, Pfizer, and sanofi-aventis
But until the emerging markets actually emerge and can pay top dollar for these drugs, the added bonus for selling there isn't likely to be that great. Development of new drugs will still be what drives drug companies for the foreseeable future.
Fortunately, with its numerous partnerships with development-stage drugmakers, Glaxo has that covered too.
More Foolishness emerges below:
Novartis is a Motley Fool Global Gains recommendation. Investing internationally doesn't have to be scary, and it can certainly be profitable. Click here to grab a 30-day trial subscription to the newsletter where you'll see all of our current picks for a global economy.